ERBB2 and breast cancer: Going beyond HR+/HER2- BC, here we aim to analyze the biology and clinical implication of PIK3CA mutations in HER2-positive (HER2+) and triple-negative BC (TNBC), focusing on preclinical and clinical evidence.